Search clinical trials for: CC-92480

Total 833 results

Jules Bordet Institute

Withdrawn

Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management (ProsPERo)

Prostate Cancers
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; H. Lee Moffitt...

Completed

Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
M.D. Anderson Cancer Center

Recruiting

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Myeloma Multiple

United States
Celgene

Completed

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, United Kingdom, Australia, Poland, Spain, Belgium, Italy, Germany, France, Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

Unspecified Childhood Solid Tumor, Protocol Specific | Childhood Myelodysplastic Syndromes | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With... and other conditions

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants

Healthy Volunteers

United States
Southeast Retina Center, Georgia
Genentech, Inc.

Completed

Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

Polypoidal Choroidal Vasculopathy

United States
Andrei Iagaru

Completed

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | PSA Failure

United States
Bristol-Myers Squibb

Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada, Taiwan, United States, Australia, Denmark, China, Korea, Republic of, Israel, Spain, France, Germany, Czechia, Austria, Japan, Sweden, United Kingdom, Greece, Italy, Finland, Argentina, Belgium, Brazil, Colombia, Hong Kong, India, Mexic... and more
Chang Gung Memorial Hospital

Completed

The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

Metastatic Prostate Cancer

Taiwan
Chang Gung Memorial Hospital

Recruiting

68Ga-PSMA PET/CT for Ra223 Assessment

Metastatic Prostate Cancer

Taiwan
SWOG Cancer Research Network
National Cancer Institute (NCI); Janssen, LP

Recruiting

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Multiple Myeloma

United States, Canada
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
Thomas Hope

Completed

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients (PSMA PET)

Prostate Cancer

United States
Celgene Corporation

Completed

A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Multiple Myeloma

United States
Gilead Sciences

Completed

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Myeloid Malignancies

United States, Australia, United Kingdom
Peking Union Medical College Hospital

Active, not recruiting

[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients

Insulinoma

China
University of Washington
Novartis; Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Neurofibromatosis Type 1 | Recurrent Childhood Pilocytic Astrocytoma | Recurrent Childhood Visual Pathway Glioma

United States, Canada, Australia, New Zealand
Weill Medical College of Cornell University
POINT Biopharma

Suspended

Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom Macroglobulinemia

United States
Celgene

Completed

Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Celgene

Completed

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease (SCD-001)

Anemia, Sickle Cell

United States
La Jolla Pharmaceutical Company

Completed

A Study of LJPC-501 in Pediatric Patients With Hypotension

Sepsis | Catecholamine-resistant Hypotension (CRH) | Distributive Shock | High Output Shock

United States
Children's Hospital of Philadelphia
Agency for Healthcare Research and Quality (AHRQ); Devereux Center for Effective...

Enrolling by invitation

Evaluation of a Remote Training Strategy

Behavior Disorders

United States
Southeast Retina Center, Georgia
Genentech, Inc.

Completed

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

Polypoidal Choroidal Vasculopathy

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

Secondary Acute Myeloid Leukemia | Alkylating Agent-Related Acute Myeloid Leukemia

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission

United States
Celgene
Triphase

Completed

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Glioblastoma | Malignant Glioma

United States, Canada
Children's Oncology Group

Not yet recruiting

A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis
Weill Medical College of Cornell University

Recruiting

Re-treatment 225Ac-J591 for mCRPC

Prostate Cancer

United States
Celgene

Completed

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q (MDS-005)

Anemia

United States, Belgium, Spain, United Kingdom, Austria, Canada, Germany, Portugal, France, Australia, Israel, Japan, Italy, Czechia, Poland, Turkey
National Cancer Institute (NCI)

Withdrawn

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Weill Medical College of Cornell University
National Cancer Institute (NCI); United States Department of Defense; National... and other collaborators

Completed

Phase I Trial of 225Ac-J591 in Patients With mCRPC

Prostate Cancer

United States
Ankara City Hospital Bilkent

Completed

Efficacy of Pulse Radiofrequency Treatment in Patients With Coxarthrosis

Coxarthrosis; Primary

Turkey
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

Graft-versus-Host Disease

United States
Celgene

Active, not recruiting

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. (MAGNIFY)

Lymphoma, Non-Hodgkin

United States, Germany, Puerto Rico
National Cancer Institute (NCI)

Completed

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Hodgkin Lymphoma | B-Cell Lymphoma | Relapsed B-cell NHL

United States
National Cancer Institute (NCI)

Completed

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Neurofibromatosis Type 1 | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Visual Pathway Glioma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Amgen

Completed

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. (UNVEIL)

Parapsoriasis

United States
Ramathibodi Hospital
Khon Kaen University

Completed

Combined Corticosteroid With Low Volume Compared to High Volume in Impingement Syndrome

Impingement Shoulder
Northwestern University
National Cancer Institute (NCI)

Withdrawn

Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Leptomeninges

United States
KAZM Pharmaceuticals Inc.
McMaster University

Not yet recruiting

Multiprofen-CC™ to Reduce Pain After Total Knee Arthroplasty

Postsurgical Pain

Canada
M.D. Anderson Cancer Center
Celgene Corporation

Active, not recruiting

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

Lymphoma

United States
National Human Genome Research Institute (NHGRI)

Completed

Treatment Strategies for Children With Smith-Magenis Syndrome

Mental Retardation | Sleep Disorders, Circadian Rhythm | Developmental Delay Disorders | Chromosome Deletion | Self Injurious Behavior

United States
Celgene

Completed

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) (AUGMENT)

Lymphoma, Non-Hodgkin

United States, Spain, China, Belgium, France, United Kingdom, Israel, Turkey, Russian Federation, Italy, Brazil, Czechia, Portugal, Germany, Japan, Poland, Puerto Rico

Search clinical trials for: CC-92480

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations